Neil Kumar, BridgeBio

Bridge­Bio team clears a key hur­dle with their proof-of-con­cept da­ta for a rare ge­net­ic dis­ease. And they can thank the NIH for a quick suc­cess

Bridge­Bio’s Cal­ci­lytix team has sev­er­al good rea­sons to of­fer some spe­cial thanks to the NIH to­day.

Mike Collins, an NIH re­searcher and di­vi­sion chief who spe­cial­izes in bone and min­er­al me­tab­o­lism, sug­gest­ed the idea that the right cal­ci­um sens­ing re­cep­tor (CaSR) an­tag­o­nist could pro­vide a di­rect way to treat a rare dis­ease called ADH1, a ge­net­ic ail­ment that trig­gers a dan­ger­ous im­bal­ance in cal­ci­um in a small pa­tient pop­u­la­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.